This program is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, and other healthcare professionals who care for patients with NF1-associated tumors.
The goal of this program is to improve the knowledge, confidence, and competence of learners to apply recent findings and integrate new and emerging agents into the treatment of patients with NF1-associated tumors.
Upon completion of this activity, participants should be able to:
Explain the relevance of NF1 gene alterations and the RAS/MAPK signaling pathway in the pathogenesis of neurofibromas and other NF1-associated tumors
Evaluate the rationale for the use of MEK inhibiting agents and other investigational targeted therapies for the treatment of NF1-related benign and malignant tumors
Incorporate MEK inhibitors into treatment plans for patients with NF1-associated plexiform neurofibromas based on the latest evidence, recommendations, and individual patient and tumor characteristics
Apply supportive care strategies to manage both common and rare toxicities associated with MEK inhibitor therapy in NF1-associated plexiform neurofibromas
Assess current data on potential expanded indications and emerging agents in NF1 to prepare for efficient integration of emerging therapies into clinical practice
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Jaishri Blakeley, MD
The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Director, The Neurofibromatosis Therapeutic Acceleration Program
Director, The Johns Hopkins Comprehensive Neurofibromatosis Program
Department of Neurology, Neruo-Oncology
The Johns Hopkins School of Medicine
Jaishri Blakeley, MD, FAAN: consultant/advisor/speaker: SpringWorks Therapeutics.
Miriam Bornhorst, MD
Gilbert Neurofibromatosis Clinic
Cancer Genetics Clinic
Department of Neurology and Oncology
Center for Genetics Medicine Research
Children's National Hospital
Assistant Professor of Pediatrics
George Washington University
Miriam Bornhorst, MD: consultant/advisor/speaker: Alexion.
Michael J. Fisher, MD
Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Professor of Pediatrics
Division of Oncology
The Children’s Hospital of Philadelphia
Michael Fisher, MD: consultant/advisor/speaker: AstraZeneca, Day One, Springworks; researcher: Array BioPharma, AstraZeneca, Exelixis.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 30, 2023, through November 29, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity